# Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions - Link: https://www.thailand-business-news.com/pr-news/ascletis-to-present-data-on-multiple-programs-at-the-american-diabetes-associations-2026-scientific-sessions - Published: 2026-04-30T07:10:00+07:00 - Author: PR Newswire | | HONG KONG, April 30, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association’s (ADA’s) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of ASC39, an eloralintide-like selective and potent oral small molecule amylin receptor agonist for the treatment of obesity. **Presentation details** **Title: **ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity **Session:** Late Breaking Poster Session (3067-LB) **Date/Time:** Sunday, June 7, 2026, 12:30 PM CT **Title:** Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity **Session:** Sunday General Poster Session (1672-P) **Date/Time:** Sunday, June 7, 2026, 12:30 PM CT **Title:** ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies **Session:** Sunday General Poster Session (1673-P) **Date/Time: **Sunday, June 7, 2026, 12:30 PM CT Additional information about the ADA’s 2026 Scientific Sessions is available at the ADA meeting website ([American Diabetes Association](https://professional.diabetes.org/scientific-sessions/program-information)). **About Ascletis Pharma Inc.** Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence- assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform ( ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit [www.ascletis.com](https://www.ascletis.com/). Contact: Peter Vozzo ICR Healthcare443-231-0505 (U.S.)[Peter.vozzo@icrhealthcare.com](https://www.thailand-business-news.com/pr-news/Peter.vozzo@icrhealthcare.com) Ascletis Pharma Inc. PR and IR Teams +86-181-0650-9129 (China)[pr@ascletis.com](https://www.thailand-business-news.com/pr-news/pr@ascletis.com) [ir@ascletis.com](https://www.thailand-business-news.com/pr-news/ir@ascletis.com) --- | This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. | --- **Read the original article :** [Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions ](http://www.prnasia.com/story/archive/4946582_AE46582_0?rand=184833)